Karen Fallen

Karen began her role as Chief Executive Officer of Touchlight DNA Services in November 2020, the CDMO business forms part of the Touchlight group and is responsible for the development, manufacture, and deployment of Touchlight’s proprietary dbDNA technology to customers within the gene therapy and broader healthcare markets.

In her most recent role prior to joining TDS, Karen served as President, Business Unit Head, and Mammalian and Microbial Development and Manufacturing for Lonza Pharma & Biotech. This business unit enabled Lonza’s customers to successfully develop and supply new biotherapeutics for patients by employing innovation in custom development and manufacturing across multiple technologies and throughout the drug life cycle.

Karen has worked in the CDMO area of the Life Sciences Industry for 31 years holding various roles at Celltech and Lonza leading Business Units, global Sales / Business Development, Licensing teams, and Operational Quality.

Karen has a BSc (Hons) in Applied Biology.